Introduction {#s1}
============

Patients with severe asthma experience poorer quality of life and are at an increased risk of exacerbations, hospitalisations and death due to poor disease control \[[@C1]--[@C3]\]. Since 2006, achieving good asthma control in these patients has been the cornerstone of the Global Initiative for Asthma (GINA) management strategy aiming to reduce the impact of the disease on patients\' daily activities \[[@C4], [@C5]\]. However, several real-life surveys have shown that asthma control still remains an unmet goal \[[@C6]\].

Previous surveys have reported the major impact of asthma on patients\' lives due to the lack of control \[[@C7]--[@C9]\]. Many patients with severe persistent asthma were unable to lead regular lives due to a low level of asthma control \[[@C10]--[@C12]\]. Notably, approximately half of patients who were clinically adjudged to have severe persistent symptoms considered their asthma to be well controlled \[[@C10], [@C13]\].

Fighting for Breath was a large-scale survey, conducted by the European Federation of Allergy and Airways Diseases Patients\' Associations (EFA) between 2004 and 2005, to understand the impact of severe asthma on patients\' lives \[[@C14], [@C15]\]. The results indicated that the majority of patients with severe asthma experienced substantial limitations in their life as a consequence of the uncontrolled disease. However, substantial time has passed since such a large-scale survey has been performed, specifically in patients with severe asthma \[[@C10], [@C13]--[@C15]\].

We conducted a large, global, real-life survey, Still Fighting for Breath, aimed to assess the current impact of severe persistent asthma on patients\' daily lives and activities. This survey provides a well-timed evaluation to determine whether disease control and management of patients with severe persistent asthma have changed in recent years.

Methods {#s2}
=======

Participants {#s2a}
------------

Adult patients aged \>18 years and caregivers of patients aged 6--17 years (paediatric and adolescent patients) with severe persistent asthma were included in this survey. Participants were enrolled from nine countries (UK, Germany, France, Italy, Spain, Brazil, Canada, Japan and Portugal). Patients and caregivers of paediatric and adolescent patients, mainly identified *via* databases (consumer panels), were invited to complete the screening questionnaire and were included in this survey only if they met the criteria for severe asthma.

Survey description {#s2b}
------------------

Data were collected using a 20-minute online survey, conducted by GfK on behalf of Novartis, between July 12, 2016 and October 31, 2016. Patients/caregivers completed the questionnaire on asthma control, daily/physical activity, exacerbations, psychological aspects and treatment.

Definition and assessment of severity {#s2c}
-------------------------------------

Experiencing severe symptoms throughout the previous year was considered as severe persistent asthma. Severity of disease was self-reported by patients based on the question: "Thinking about the severity of your/your child\'s asthma, what did your doctor tell you the last time you talked about severity?" This answer was further validated using the GINA questionnaire.

Assessment of asthma control as per GINA guidelines {#s2d}
---------------------------------------------------

Asthma control assessment according to GINA is based on four questions: In the past 4 weeks, has the patient had (yes/no): 1) ...daytime symptoms more than twice a week?; 2) ...any night waking due to asthma?; 3) ...the need for reliever medication more than twice a week?; and 4) ...any activity limitations due to asthma? Patients experiencing none of the above symptoms were categorised as well controlled; patients experiencing one or two of the symptoms were considered as partly controlled and those experiencing three or four of the symptoms were considered to be uncontrolled patients.

Results {#s3}
=======

Participants {#s3a}
------------

A total of 1333 patients were surveyed, 1181 of whom were adults and 152 were caregivers of paediatric and adolescent patients. Overall, 53% of the total survey population was diagnosed with allergic asthma, reported based on patient knowledge. The country-wise patient distribution, demographics and disease profile are shown in [table 1](#TB1){ref-type="table"}.

###### 

Distribution, demographics and disease profile of survey participants by country

                                                                    **Adult patients**   **Adolescent patients^\#^**   **Paediatric patients^\#^**   **Total**
  ---------------------------------------------------------------- -------------------- ----------------------------- ----------------------------- -----------
  **Country**                                                                                                                                       
   UK                                                                      190                       18                            11                   219
   Germany                                                                 170                       14                            10                   194
   France                                                                  170                       15                            15                   200
   Italy                                                                   116                        5                             5                   126
   Brazil                                                                  150                       10                            20                   180
   Canada                                                                  150                        3                             6                   159
   Spain                                                                   115                        4                            16                   135
   Japan                                                                    90                        0                             0                   90
   Portugal                                                                 30                        0                             0                   30
   Total                                                                   1181                      69                            83                  1333
  **Male/female %**                                                       44/56                     39/61                         27/73             
  **Mean±[sd]{.smallcaps} age years**                                                                                                               
   Male                                                                 42.0±13.3                 14.0±1.5                       8.0±1.5            
   Female                                                               44.0±13.6                 14.0±1.8                       8.0±1.8            
  **Smoking %**                                                                                                                                     
   Current smokers                                                         20.0                                                                     
   Ex-smokers                                                              24.0                                                                     
   Never smoked                                                            54.0                                                                     
   E-cigarette smokers                                                     2.0                                                                      
  **Disease duration, median years**                                       16.0                      7.0                           3.0              
  **Proportion of patients diagnosed with allergic asthma %**              52.0                     55.0                          67.0                 53.0
  **Proportion of patients diagnosed with nonallergic asthma %**           48.0                     45.0                          33.0                 47.0
  **Proportion of patients diagnosed by %**                                                                                                         
   Respiratory physician                                                                                                                               42.0
   General practitioner                                                                                                                                30.0
   Allergist                                                                                                                                           21.0
   Paediatrician                                                                                                                                        6.0
   Other                                                                                                                                                1.0

Data are presented as n, unless otherwise stated. ^\#^: data for adolescent and paediatric patients were captured through their caregivers.

Clinical and psychological impact {#s3b}
---------------------------------

In the previous year, 73% of the total population experienced at least one exacerbation, of these, 34% experienced more than two exacerbations that required emergency treatment (intervention by a healthcare professional (HCP), emergency room visit, ambulance use, or physician at home). Overall, 51% of patients who had an exacerbation that required emergency treatment clinically recovered within 24 h, although 13% required ≥1 week to recover. However, emotional/psychological recovery took longer, with 39% of patients recovering within 24 h, while 21% needed ≥1 week to recover. Of the total population, 50% reported having been clinically diagnosed with a psychological condition by an HCP. A detailed description of the impact of asthma on psychological wellbeing and daily activities is given in [tables 2](#TB2){ref-type="table"}--[4](#TB4){ref-type="table"}.

###### 

Impact of asthma on psychological wellbeing.

                                                  **Adult**   **Adolescent^\#^**   **Paediatric^\#^**   **Total**
  ---------------------------------------------- ----------- -------------------- -------------------- -----------
  **Prominent words associated with asthma %**                                                         
   Breathlessness/suffocation                       17.0             3.0                  2.0             16.0
   Bad/uncomfortable                                 6.0             7.0                  5.0              6.0
   Stress/anxiety                                    5.0             12.0                 4.0              5.0
   Fatigue/tiredness                                 4.0              0                   4.0              4.0
   Respiration                                       4.0             6.0                  1.0              4.0
   Pain/suffering                                    3.0             7.0                  4.0              4.0
   Limited                                           3.0             6.0                  1.0              3.0
  **Symptoms during exacerbations %**                                                                  
   Cough                                            59.0             62.0                 69.0            60.0
   Daytime wheezing                                 57.0             62.0                 52.0            57.0
   Night-time wheezing                              55.0             55.0                 57.0            55.0
   Persistent shortness of breath                   57.0             64.0                 43.0            57.0
   Breathlessness while lying down                  55.0             51.0                 43.0            54.0
   Fatigue                                          52.0             55.0                 40.0            52.0
  **Associated psychological condition %**                                                             
   Anxiety                                          40.1             42.0                 39.0            18.0
   Depression                                       28.2             30.0                 13.0            10.0
   Other psychological condition                     3.0              0                    0               2.0
   None of the above                                47.0             54.0                 78.0            49.0
  **Overall psychological impact %**                                                                   
   Feel limited because of asthma                   47.0             42.0                 25.0            45.0
   Feel dependent on the medication                 41.0             25.0                 23.0            39.0
   Feel scared because of potential attack          34.0             33.0                 27.0            33.0
   Able to deal with asthma                         30.0             36.0                 34.0            31.0

^\#^: data for adolescent and paediatric patients were captured through their caregivers.

###### 

Distribution of anxiety and depression by country

  **Country**     **Prevalence in severe asthma patients**^\#^ **%**   **Prevalence in general population**^¶^ **%**        
  -------------- ---------------------------------------------------- ----------------------------------------------- ----- -----
  **Global**                             40.1                                              28.2                        3.6   4.4
  **UK**                                 39.7                                              35.6                        4.2   4.5
  **Germany**                            36.1                                              40.7                        5.8   5.2
  **France**                             41.5                                              20.5                        6.2   4.8
  **Italy**                              51.6                                              29.4                        5.0   5.1
  **Brazil**                             46.7                                              27.2                        9.3   5.8
  **Canada**                             38.4                                              28.9                        4.9   4.7
  **Spain**                              29.6                                              21.5                        4.1   5.2
  **Japan**                              40.0                                              13.3                        3.1   4.2
  **Portugal**                           30.0                                              16.7                        4.9   5.7

^\#^: results from the Still Fighting for Breath survey; ^¶^: results from World Health Organization report \[34\].

###### 

Impact of asthma on daily activities in patients with severe persistent asthma

                                                              **Adult**   **Adolescent^\#^**   **Paediatric^\#^**   **Total**
  ---------------------------------------------------------- ----------- -------------------- -------------------- -----------
  **Impact on patients' lives %**                                                                                  
   Disruption of activities of daily living                     89.0             84.0                 67.0            88.0
   Disruption of physical activities                            84.0             90.0                 89.0            84.0
   Disruption of sleep                                                                                                97.0
   Negative impact on self-esteem                               53.0             45.0                 32.0            51.0
   Negative impact on professional life                         58.0           36.0^¶^                55.0         
  **Wellbeing assessment %**                                                                                       
   Felt cheerful and in good spirits                             4.0            3.0^¶^                4.0          
   Felt calm and relaxed                                         5.0            3.0^¶^                5.0          
   Felt active and vigorous                                     11.0            2.0^¶^                10.0         
   Woke up feeling fresh and relaxed                            15.0            9.0^¶^                14.0         
   Daily life has been filled with things that interest me       6.0            5.0^¶^                6.0          

^\#^: data for adolescent and paediatric patients were captured through their caregivers. ^¶^: Data are reported for the caregivers of the adolescent and paediatric patients.

Impact on daily and professional lives {#s3c}
--------------------------------------

The majority of patients reported disruption of "physical activities" (84%), "activities of daily living" (88%) and "sleep" (97%). Of the total population, 58% of adult patients and 36% of caregivers perceived asthma to be negatively affecting their professional working lives, with the main factors being "not able to concentrate", "taking time off due to asthma", and "not being able to be fully productive".

Asthma control {#s3d}
--------------

In the total population, a large discrepancy was observed between the proportion of patients who perceived their asthma to be well controlled (42%) and the proportion of patients who were reported as well controlled as per GINA assessment (6%); similar discrepancies were also observed in the adult, adolescent and paediatric subpopulations ([figure 1](#F1){ref-type="fig"}).

![Level of control a) as perceived by patients, and b) as per the Global Initiative for Asthma control questionnaire. Rounding differences may be observed for these data.](00076-2018.01){#F1}

Most patients (91%) who used oral corticosteroids (OCSs) for ≥14 days (high OCS users) perceived their disease to be either partly controlled or well controlled; however, only 38% of these patients were partially or well controlled as per GINA assessment. There was a strong disconnect between the patient\'s perception and GINA assessment of disease control in both low and high OCS users ([figure 2](#F2){ref-type="fig"}).

![Level of control in a) high oral corticosteroid users and b) low oral corticosteroid users. Rounding differences may be observed for these data. GINA: Global Initiative for Asthma.](00076-2018.02){#F2}

Treatment {#s3e}
---------

Of the total population, 58% of patients received short-acting rescue medication on top of the maintenance treatment. The mean duration of OCS use was reported to be 20 days in the last 6 months, while 63% of patients surveyed used OCSs on fewer than 14 days in the last 6 months (low OCS users).

Discussion {#s4}
==========

The observed impact of severe asthma on patients included in our survey was similar to that reported in the Fighting for Breath survey conducted in 2005 \[[@C14], [@C15]\]. Comparison of key parameters between the Fighting for Breath and Still Fighting for Breath surveys is presented in [table 5](#TB5){ref-type="table"}. It should be noted that a comparison in terms of the extent of asthma control between the two surveys may not be possible as assessment of control was not included in the GINA guidelines when the previous survey was performed.

###### 

Comparison of Fighting for Breath and Still Fighting for Breath survey results

  **Parameter**                                      **Fighting for Breath survey**    **Still Fighting for Breath survey**
  ------------------------------------------------- -------------------------------- ----------------------------------------
  **Year of study**                                               2005                                 2016
  **Total population n**                                          1300                                 1333
  **Disturbed sleep %**                                 42.0 (about once a week)                       97.0
  24.0 (more than once week)                                                         
  **Wheezing %**                                        42.0 (about once a week)                       57.0
  24.0 (more than once week)                                                         
  **Missed going out with friends %**                             38.0                                 52.0
  **Missed out job opportunities %**                              21.0                24.0 (I worry that I will lose my job)
  **Missed holidays %**                                           28.0                                 39.0
  **Physical activities %**                                       84.0                                 69.0
  **Missed joining in at school or at college %**                 14.0                                 20.0
  **Having pets %**                                               49.0                                 40.0

However, our results suggest that most patients with severe asthma still experience a lack of control and poor quality of life. Our survey also shows that there is a significant disconnect between guideline-defined asthma control and patient-perceived asthma control in patients with severe asthma. This was reflected in the large discrepancy observed between the proportion of patients who perceived their asthma to be well controlled (42%) and the proportion of patients who were reported as well controlled as per GINA assessment (6%). As per our survey, only 58% of patients reported that they were taking short-acting β-agonists (SABAs) on top of the maintenance therapy. However, we would expect that all patients used SABA as a reliever medication. We believe that the misperception of asthma control may have led to the nonusage of SABAs by all patients, considering that from the 42% that believed their asthma was well controlled, only 6% were well controlled as per the GINA assessment. These 42% were not using SABAs as reliever medication. However, due to the design of the survey it cannot be determined if these patients were also not well educated, were nonadherent or were using additional long-acting muscarinic antagonists (LAMAs) and/or monoclonal antibodies instead of SABAs. There are reports about asthmatics using biologics showing a reduction in SABA use \[[@C16]\].

Several factors may be responsible for this lack of asthma control, including inadequate or non-personalised disease-management support for individuals, inappropriate pharmacological treatment, nonadherence or inadequate adherence to medication, poor inhaler technique and poor adherence to the overall asthma management plan, and lack of referral to a specialist or poor diagnosis/asthma management by the HCP \[[@C4], [@C17], [@C18]\].

In the Fighting for Breath survey, patients were asked to indicate the possible reasons for their poor quality of life. The three major reasons reported were exposure to passive smoking, lack of treatment by a specialist and absence of new treatments \[[@C14], [@C15]\]. Consequently, in the past decade, various steps have been taken to improve the quality of life of asthma patients. These include: implementation of laws banning smoking in public spaces \[[@C19], [@C20]\], introducing new treatments such as monoclonal antibody-based therapies \[[@C21]\], and guideline-recommended new indication of LAMAs \[[@C22]\] for the effective treatment of patients with asthma. After a decade, our results show that patients with asthma still have a poor quality of life and experience symptoms that affect their daily lives. Though it should be noted that there is no information whether patients included in our survey were eligible for (or on), monoclonal antibody-based therapies.

Proper perception of control is associated with improved asthma-related health status as well as decreased prospective risk for severe exacerbations \[[@C23]\]. Patients\' perception of asthma control can influence both adherence to treatment and care by physicians; a better understanding of disease and disease control is therefore important in order to achieve optimal treatment outcomes and improve asthma management \[[@C24], [@C25]\]. Poor perception of symptoms may lead to incorrect or under-treatment resulting in increased morbidity and mortality from asthma \[[@C26]\]. Various factors have been associated with this poor perception of control. These include smoking \[[@C27], [@C28]\], psychological factors such as anxiety and depression (common in people with severe asthma) \[[@C29], [@C30]\], obesity, physical inactivity \[[@C31]\], and low educational status. There have also been efforts to further educate HCPs to take informed decisions on when to refer patients with severe asthma to specialist centres and to educate patients on ways to understand and recognise their disease condition and symptom control \[[@C32], [@C33]\]. However, the results of our survey show that patients with severe asthma still have a poor perception of symptom control leading to poor quality of life, but if we are to empower patients this cannot be placed as the fault of the individual. Although a majority of patients perceived their asthma to be controlled, many still experienced frequent symptoms that affected their daily lives, and 73% of patients reported exacerbations that required HCP intervention. Furthermore, proportion of population suffering from psychological condition in this survey (anxiety, 40.1%; depression, 28%) was substantially higher than observed in general population (anxiety, 3.6%; depression, 4.4%) \[[@C34]\] ([table 3](#TB3){ref-type="table"}). This suggests that a high proportion of patients "had a poor perception of their asthma" and did not recognise the extent of their symptoms due to asthma, thus tending to overestimate their disease control.

Hence, we propose to include perception of control in patients with asthma as a crucial component of disease assessment and management in order to facilitate improving control in these patients.

The current survey results also highlight that depression and anxiety due to asthma maybe important conditions that are either not revealed or are underestimated. Namely, half of the population surveyed here reported being diagnosed with a psychological condition, with the majority of the patients suffering from anxiety and depression, which is similar to the findings reported previously \[[@C35], [@C36]\].

There are some limitations of this survey: data presented herein were obtained *via* an online survey; hence, the data were self-reported by patients or their caregivers and were not clinically verified and thus, inaccurate responses due to poor recall cannot be excluded. Moreover, it is difficult to precisely predict the actual factors behind participant responses. Data for minor patients were reported by their caregivers; these responses may not be reflective of the actual situation, especially the smoking status among these patients. The definition of severe asthma was based on patient-reported symptom history in the past year and was not as definitive as provided by the guidelines.

Overall, our survey highlights that a substantial gap remains between guideline-defined and patient-perceived asthma control in patients with severe asthma. Over a decade after the Fighting for Breath survey was conducted, little seems to have changed in terms of the quality of life of patients with severe asthma. Severe asthma patients still live with uncontrolled asthma, experience exacerbations, suffer from psychological symptoms and have an unacceptable level of quality of life. Moreover, patients\' perception of "asthma control", and their expectations of "good asthma control" appear alarmingly low. This is despite a decade of increased research and resource provision in severe asthma, multiple changes to guidelines and new advancements in pharmacological intervention. Severe asthma patients are Still Fighting for Breath and we advocate a thorough reconsideration of our approach to the management of severe asthma ([figure 3](#F3){ref-type="fig"}). If no action is taken, it is unlikely that the next 10 years will see any substantial change in the quality of lives of severe asthma patients in all age groups. Our proposals are: to develop tools to assess asthma symptom perception and to subsequently include such a measure in the routine assessment of patients with asthma; and to reinforce the education of asthma patients through HCPs and patient organisations.

![Holistic approach for severe asthma management.](00076-2018.03){#F3}

Conclusions {#s5}
-----------

This large-scale global survey showed that severe persistent asthma has a major impact on patients, affecting their daily and professional activities, and having a negative impact on their psychological condition. Most patients with severe asthma remain inadequately controlled. In addition, there is a strong disconnect between guideline-defined and patient-perceived asthma control. Thus, there is a need for improved management (support and strategies) of patients with severe persistent asthma and better coordination of efforts including those aimed at enhancing asthma education, assessing perception of control, patient--physician interaction, guideline implementation, treatment adherence and involvement of patient organisations. Implementation of these measures would go some way to enabling these patients to achieve better disease control.
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